Just In
- 2 hrs ago New Book ‘Kathmandu Chronicle: Reclaiming India-Nepal Relations’ To Shed Light On Geopolitical Uncertainties
- 6 hrs ago Russian Influencer Starves His Newborn To Death With Sunlight Diet, Know Dos And Don’ts Of This Diet
- 9 hrs ago Mahavir Jayanti 2024: Date, Time, History, Celebrations And Teachings Of Lord Mahavir In Jainism
- 10 hrs ago Parineeti Chopra Saree Looks: Check Amar Singh Chamkila Actor's Regal Fashion Statements
Don't Miss
- Education UP Board Result 2024: 82% of Jail Inmates Passed the Class 12 and 97% of the Class 10
- News Bengaluru Water Crisis: PM Modi Slams Karnataka Congress, Says Mismanagement Turned Tech City To Tanker City
- Movies Queen Of Tears Episode 14 OTT Release Date, Time, Platform: When & Where To Watch? What To Expect? DEETS Out
- Automobiles Tata Altroz Records a 55% Sales Growth in March 2024
- Sports IPL 2024: DC vs SRH Live Score & Updates; Travis Head smashes 16-ball fifty; SRH off to a blistering start
- Finance Rs 17.50/Share Dividend: Tata Mid Cap To Consider Dividend On April 29, LIC Stake 9.88%
- Technology Best Noise-Cancelling Earbuds Under Rs 5,000: CMF Buds Pro, Redmi Buds 5, Realme Buds Air 5, and More
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
Pfizer, Astrazeneca COVID Vaccines Generate More Antibodies Than Natural Infection: Study
People who receive the Pfizer or AstraZeneca COVID-19 vaccine have antibody levels significantly higher than those infected with the SARS-CoV-2 virus, according to a study published in Scientific Reports journal on Monday.
A team led by researchers at the University of Montreal in Canada found that these antibodies were also effective against the Delta variant.
In the study, 32 non-hospitalised COVID-19 positive Canadian adults were recruited 14 to 21 days after being diagnosed through PCR testing in 2020, before the Beta, Delta and Gamma variants emerged.
"Everyone who had been infected produced antibodies, but older people produced more than adults under 50 years of age," said Jean-Francois Masson, a professor at the University of Montreal.
"In addition, antibodies were still present in their bloodstream 16 weeks after their diagnosis," Masson said.
Antibodies produced after an infection by the original viral strain also reacted to SARS-CoV-2 variants that emerged in subsequent waves, namely Beta, Delta and Gamma, with a reduction of 30 to 50 per cent in reactivity.
"But the result that surprised us the most was that antibodies produced by naturally infected individuals 50 and older provided a greater degree of protection than adults below 50," said Joelle Pelletier, a professor at the University of Montreal.
"This was determined by measuring the antibodies' capacity to inhibit the interaction of the Delta variant's spike protein with the ACE-2 receptor in human cells, which is how we become infected," he added.
The researchers, however, did not observe the same phenomenon with the other variants.
They noted that when someone who has had a mild case of COVID is vaccinated, the antibody level in their blood doubles compared to an unvaccinated person who has been infected by the virus.
Their antibodies are also better able to prevent spike-ACE-2 interaction, according to the researchers.
"But what's even more interesting is that we have samples from an individual younger than 49 whose infection didn't produce antibodies inhibiting spike-ACE-2 interaction, unlike vaccination," said Masson.
"This suggests that vaccination increases protection against the Delta variant among people previously infected by the native strain," Masson added.
The researchers believe more research should be conducted to determine the best combination for maintaining the most effective level of antibodies reactive to all variants of the virus.
- wellnessPaxlovid: South Korea Gets First Supply Of Pfizer's COVID-19 Pills; Read Details
- healthCOVID-19: Pfizer Vaccine's Booster Shot Can Cut Mortality From Delta Variant By 90 Per Cent: Study
- healthPfizer Vaccine Provides Partial Protection Against Omicron: Study
- healthPfizer’s Pill Is The Latest COVID Treatment To Show Promise. Here Are Some More
- disorders cureMixing And Matching Of COVID-19 Vaccine Doses? Is It Safe?
- wellnessAstrazeneca Covid-19 Booster Shot Effective Against Severe Disease, UK Study Finds
- healthAstrazeneca Vaccine As Third Dose Effective Against Omicron: Study
- wellnessGap Between Second And Precaution Dose Of Covid-19 Vaccine Reduced To 6 Months
- wellnessNovel Inhalable Covid-19 Vaccine Is Stable At Room Temperature: Study
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap
- wellnessEven Vaccinated People Can Develop Long Covid, Study Finds
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study